Abstract
Metabolic syndrome, a “cluster” of metabolic disorders including hypertension, increases the cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this syndrome antihypertensive treatment with betablockers is underused because of their adverse metabolic effects. The aim was to review the evidences supporting the reasons for under-using beta-blockers in hypertensive patients with metabolic syndrome. A review of Literature has been carried out via PubMed from 1998 to 2008: most of beta-blockers have adverse effects on insulin sensitivity, carbohydrate and lipid metabolism, and are not recommended in metabolic syndrome. However, some recent large studies have shown a better metabolic profile with newer third generation vasodilating beta-blockers, such as Carvedilol and Nebivolol. Vasodilating action of Carvedilol and Nebivolol, due respectively to alpha1-blocking effect and release of nitric oxide, explains the lack of adverse metabolic effects of these beta-blockers that could also be used in hypertensive patients with metabolic syndrome.
Keywords: Antihypertensive, Beta-blockers, Metabolic syndrome
Current Diabetes Reviews
Title: Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review
Volume: 6 Issue: 4
Author(s): Angelo M. Carella, Giuseppe Antonucci, Matteo Conte, Michele Di Pumpo, Armando Giancola and Elisabetta Antonucci
Affiliation:
Keywords: Antihypertensive, Beta-blockers, Metabolic syndrome
Abstract: Metabolic syndrome, a “cluster” of metabolic disorders including hypertension, increases the cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this syndrome antihypertensive treatment with betablockers is underused because of their adverse metabolic effects. The aim was to review the evidences supporting the reasons for under-using beta-blockers in hypertensive patients with metabolic syndrome. A review of Literature has been carried out via PubMed from 1998 to 2008: most of beta-blockers have adverse effects on insulin sensitivity, carbohydrate and lipid metabolism, and are not recommended in metabolic syndrome. However, some recent large studies have shown a better metabolic profile with newer third generation vasodilating beta-blockers, such as Carvedilol and Nebivolol. Vasodilating action of Carvedilol and Nebivolol, due respectively to alpha1-blocking effect and release of nitric oxide, explains the lack of adverse metabolic effects of these beta-blockers that could also be used in hypertensive patients with metabolic syndrome.
Export Options
About this article
Cite this article as:
M. Carella Angelo, Antonucci Giuseppe, Conte Matteo, Di Pumpo Michele, Giancola Armando and Antonucci Elisabetta, Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review, Current Diabetes Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339910791658844
DOI https://dx.doi.org/10.2174/157339910791658844 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 1
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Preface: EDITORIAL COMMENT “Perfect 24-hr Blood Pressure Control” From Morning to Nocturnal Hypertension: Up-To-Date 2015
Current Hypertension Reviews Astrocytes: From the Physiology to the Disease
Current Alzheimer Research The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Renin Angiotensin System Gene Polymorphisms in Response to Antihypertensive Drugs and Visit-To-Visit Blood Pressure Variability in Essential Hypertensive Patients
Current Pharmacogenomics and Personalized Medicine Beyond Mitochondria, What Would be the Energy Source of the Cell?
Central Nervous System Agents in Medicinal Chemistry TP Receptor as a Therapeutic Target in Atherosclerosis and Related Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Vascular Calcifications in Chronic Kidney Disease: Are There New Treatments?
Current Vascular Pharmacology Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?
Current Cancer Drug Targets Physical Exercise and Major Depressive Disorder - Where Do We Stand?
Current Psychopharmacology Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Postprandial Lipemia in Children and Adolescents
Current Vascular Pharmacology Design, Synthesis and Biological Evaluation of Benzopyran Derivatives as KATP Channel Openers
Letters in Drug Design & Discovery Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Combination of Thiazide Diuretics and Angiotensin Receptor Blockers Attenuates Osteoporosis in Hypertensive Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)